All Is Unfair in Cancer and Hurricanes

Article

One cancer patient’s story of being impacted by both hurricanes Harvey and Irma.

Peptide receptor radionuclide therapy (PRRT) is an exciting treatment for neuroendocrine tumors (NETs). While considered investigational because of its pending status at the FDA, Europe has performed this therapy with a high success rate for over a decade.

When a May Gallium-68 scan found microscopic tumors, my specialist recommended I pursue this treatment. It took a lot of coordinating, but I was able to access this therapy at a facility in Houston under Texas’s Right to Try law, a preferred option compared to traveling to Europe.

My first treatment went great, leaving me virtually symptom-free and slashing my blood tumor marker a whopping 75 percent. Investigational therapies are not always covered by insurance, so it was also pretty exciting when I found my insurance company paid for the treatment.

Life was looking like sunshine and kittens, so my husband and I decided the next trip to Houston should not be completely about cancer. So, we booked a romantic beach weekend in Galveston before my next therapy, scheduled for Aug. 31.

Cancer has already taught me to quickly develop back-up plans, so when the Houston clinic called to explain there could be a delay due to the approaching hurricane, I jumped into action, developing a Plan B and Plan C. Little did I know after all the events transpired, I’d end up on Plan F.

Plan A - Fly from Nashville to Houston to enjoy a weekend on the beach in Galveston before returning to Houston for treatment.

Plan B - Take the scheduled flight to Houston, drive to Dallas for the weekend. Return to Houston when the storm passes.

Plan C - Drive from Nashville, stopping to visit Memphis, Little Rock and Dallas, where we would wait for the green light.

Plan D - Reschedule therapy until Sept. 12, the one week my husband had an important commitment.

Plan E - Get my older brother lined up to take my husband’s place by booking him a flight out of Tampa Sept. 10. Enter Hurricane Irma.

Plan F - Break my husband’s commitment so he can come with me to Houston and spend the next few days calling airlines, hotels, etc. to reschedule...yet again.

While all of this was unfolding, I could rationalize that it would have been pointless for me to try to enter Houston during the chaos or for my brother to leave his family in the midst of a disaster, but still, it was stressful. Cancer already creates feelings of powerlessness, fear and uncertainty. Piling on more seems unfair. Before I spun into a ball of anxiety, I stopped and gave myself an attitude and perspective adjustment. I am lucky my situation is not critical, because there were/are others impacted by cancer who had/will have urgent situations in the midst of these disasters. Rescheduling is a minor inconvenience when a hurricane is barreling toward your home.

As I rationalized and calm myself, I realized the similarities between hurricanes and cancer. Both are natural disasters, with human-contributing factors. Both are completely unfair. Both can be devastating by taking everything you have. Both have the potential to create resilience. Both can bring out the best in people. Both create perspective because when we or our loved ones are in danger, the stresses of daily life don’t seem so stressful. And both are reminders that there is so much we cannot control.

“If plan A doesn't work, the alphabet has 25 more letters - 204 if you're in Japan.” - Claire Cook

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL